Andrea Cottignies-Calamarte
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Andrea Cottignies-Calamarte has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Timothée Bruel
Université Paris Cité, Antiviral Activities of Antibodies Group
5 shared publications Alejandro De Cruz
Université Paris Cité, Antiviral Activities of Antibodies Group
3 shared publications- Cyril Planchais
Humoral Immunology Unit, Institut Pasteur, Université Paris Cité, Paris, France
3 shared publications Florence Guivel-Benhassine
Université Paris Cité, Virus and Immunity Unit
3 shared publications- Hugo Mouquet
Institut Pasteur, Université Paris Cité, Humoral Immunology Unit, Paris, France
3 shared publications - Isabelle Staropoli
Virus and Immunity Unit, Institut Pasteur, Université Paris Cité, Paris, France
3 shared publications
Latest Publications
- Open Access
- 17 November 2026
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 22 (11) , e1014799
TMPRSS2 reduces antibody recognition of SARS-CoV-2 spike
The serine protease TMPRSS2 acts as a cofactor for SARS-CoV-2 entry by cleaving the viral spike (S) to initiate fusion. Whether TMPRSS2 has an impact on humoral immune response against S remains poorly characterized. Here, we show that TMPRSS2 impairs antibody binding to S. In S-expressing and infected cells, TMPRSS2 decreases monoclonal antibody (mAb) and immune serum binding, as well as antibody-dependent cellular cytotoxicity (ADCC) induction. Using a panel of 39 mAbs targeting various S regions, we observe that those binding to the S2 subunit are the most affected by TMPRSS2. TMPRSS2 promotes a partial shedding of S1 and changes S2 conformation. This processing reduces Angiotensin-Converting Enzyme 2 (ACE2) binding while increasing cell-cell fusion. We further observe that the capacity of TMPRSS2 to decrease antibody recognition is conserved across coronaviruses and shared with other TMPRSS proteins. However, TMPRSS2 expression in infected cells does not impact significantly virions’ infectivity or the antibody recognition, as measured by flow virometry. Collectively, our findings suggest that TMPRSS2 processing of S favors a conformation which is less sensitive to antibody recognition.
- 17 November 2026
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 22 (11) , e1014799
Open AccessTMPRSS2 reduces antibody recognition of SARS-CoV-2 spike
The serine protease TMPRSS2 acts as a cofactor for SARS-CoV-2 entry by cleaving the viral spike (S) to initiate fusion. Whether TMPRSS2 has an impact on humoral immune response against S remains poorly characterized. Here, we show that TMPRSS2 impairs antibody binding to S. In S-expressing and infected cells, TMPRSS2 decreases monoclonal antibody (mAb) and immune serum binding, as well as antibody-dependent cellular cytotoxicity (ADCC) induction. Using a panel of 39 mAbs targeting various S regions, we observe that those binding to the S2 subunit are the most affected by TMPRSS2. TMPRSS2 promotes a partial shedding of S1 and changes S2 conformation. This processing reduces Angiotensin-Converting Enzyme 2 (ACE2) binding while increasing cell-cell fusion. We further observe that the capacity of TMPRSS2 to decrease antibody recognition is conserved across coronaviruses and shared with other TMPRSS proteins. However, TMPRSS2 expression in infected cells does not impact significantly virions’ infectivity or the antibody recognition, as measured by flow virometry. Collectively, our findings suggest that TMPRSS2 processing of S favors a conformation which is less sensitive to antibody recognition.
- 22 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (859) , eaec6027
Complement augments antibody neutralization of SARS-CoV-2 variants
The complement system is a major effector system of the humoral immune response, but its capacity to cooperate with antibodies to inhibit the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a host remains poorly characterized. Here, we combined authentic virus neutralization, antibody engineering, and single viral particle analysis by flow virometry to show that complement enhances antibody neutralization of SARS-CoV-2. Addition of complement increased neutralization titers of sera from convalescent individuals ( n = 14), vaccinated individuals ( n = 15), and individuals with hybrid immunity ( n = 15) against D614G, BA.1, XBB.1.5, and JN.1 variants by up to 42-fold. D614G and BA.1 displayed a high level of neutralization, which was only slightly improved by adding complement. Conversely, neutralization of XBB.1.5 and JN.1 was weak but strongly enhanced by complement. Among the 32 JN.1 nonneutralizers, 22 regained detectable neutralization in the presence of complement. The enhancement mainly relied on cross-reactive anti-S2 antibodies, but monoclonal antibodies targeting the receptor binding domain and N-terminal domain could also be augmented. Viral inhibition required antibody Fc hexamerization, C1q recruitment, and C3 deposition, but it was independent of the membrane attack complex formed by C9. Consistently, complement components were deposited at the surfaces of viral particles with no detectable virolysis. In sera from individuals with severe COVID-19, both complement-mediated neutralization and anti-S2 antibody levels were associated with improved survival. Overall, our data show that complement potentiates the ability of antispike antibodies to neutralize immune-evasive SARS-CoV-2 variants.
- 22 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (859) , eaec6027
Complement augments antibody neutralization of SARS-CoV-2 variants
The complement system is a major effector system of the humoral immune response, but its capacity to cooperate with antibodies to inhibit the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a host remains poorly characterized. Here, we combined authentic virus neutralization, antibody engineering, and single viral particle analysis by flow virometry to show that complement enhances antibody neutralization of SARS-CoV-2. Addition of complement increased neutralization titers of sera from convalescent individuals ( n = 14), vaccinated individuals ( n = 15), and individuals with hybrid immunity ( n = 15) against D614G, BA.1, XBB.1.5, and JN.1 variants by up to 42-fold. D614G and BA.1 displayed a high level of neutralization, which was only slightly improved by adding complement. Conversely, neutralization of XBB.1.5 and JN.1 was weak but strongly enhanced by complement. Among the 32 JN.1 nonneutralizers, 22 regained detectable neutralization in the presence of complement. The enhancement mainly relied on cross-reactive anti-S2 antibodies, but monoclonal antibodies targeting the receptor binding domain and N-terminal domain could also be augmented. Viral inhibition required antibody Fc hexamerization, C1q recruitment, and C3 deposition, but it was independent of the membrane attack complex formed by C9. Consistently, complement components were deposited at the surfaces of viral particles with no detectable virolysis. In sera from individuals with severe COVID-19, both complement-mediated neutralization and anti-S2 antibody levels were associated with improved survival. Overall, our data show that complement potentiates the ability of antispike antibodies to neutralize immune-evasive SARS-CoV-2 variants.
- Open Access
Detection and characterization of single SARS-CoV-2 viral particles by flow virometry
Virus infected cells release viral particles, which have variable protein content and are functionally diverse. Deciphering this heterogeneity remains a challenge. Here, we adapt flow virometry to detect and phenotype severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) particles. In supernatants of infected cells, we observe particles measuring 70–100 nm. The appearance of these particles is associated to the increase in viral RNA and infectivity. Sample inactivation using temperature or detergent leads to the disappearance of these particles. Using antibodies and dyes for lipid membranes and nucleic acids, we detect the spike protein, the lipid envelope and the RNA genome. We further confirm the presence of viral particles by electron microscopy. Analyzing different viral preparations demonstrate that spike detection in particles outcompetes particle concentration to predict infectivity. Antibodies against different spike epitopes enable probing of spike conformation changes in the presence of soluble ACE2. Lastly, we detect SARS-CoV-2 particles in PCR-confirmed patient nasal swabs without prior purification steps. In summary, we developed an efficient framework to detect and characterize single SARS-CoV-2 particles.
Open AccessDetection and characterization of single SARS-CoV-2 viral particles by flow virometry
Virus infected cells release viral particles, which have variable protein content and are functionally diverse. Deciphering this heterogeneity remains a challenge. Here, we adapt flow virometry to detect and phenotype severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) particles. In supernatants of infected cells, we observe particles measuring 70–100 nm. The appearance of these particles is associated to the increase in viral RNA and infectivity. Sample inactivation using temperature or detergent leads to the disappearance of these particles. Using antibodies and dyes for lipid membranes and nucleic acids, we detect the spike protein, the lipid envelope and the RNA genome. We further confirm the presence of viral particles by electron microscopy. Analyzing different viral preparations demonstrate that spike detection in particles outcompetes particle concentration to predict infectivity. Antibodies against different spike epitopes enable probing of spike conformation changes in the presence of soluble ACE2. Lastly, we detect SARS-CoV-2 particles in PCR-confirmed patient nasal swabs without prior purification steps. In summary, we developed an efficient framework to detect and characterize single SARS-CoV-2 particles.
- 7 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Compréhension des mécanismes de la protection des muqueuses contre les infections virales : cas du VIH-1 et du SARS-CoV-2
Les muqueuses sont des épithéliums formant une surface d'interaction avec le milieu extérieur et protègent l'organisme des infections qui découlent de cette interaction. Ces régions anatomiques particulières sont caractérisées par, notamment, des cellules immunitaires résidentes et une réponse IgA majoritaire. Le laboratoire a montré que la présence d'IgA anti-gp41 muqueux est un de corrélats de protection des individus exposés au VIH mais ne se séroconvertissant pas, ainsi que de macaques vaccinés par voie muqueuse. Il a été démontré que l'infusion d'anticorps chez les macaques peut induire une protection contre l'infection SIV/SHIV qui dépend de la réponse T CD8+, aussi impliquée dans le contrôle et la protection contre le VIH chez les humains. Cette observation semble indiquer un rôle de la signalisation par les FcR dans l'induction des réponses T CD8+ spécifiques du VIH mais pour laquelle les mécanismes moléculaires précis manquent de description. L'engagement des FcR sur les cellules myéloïdes induit des fonctions effectrices comme la phagocytose et sont associées à la protection des individus. Au début de cette étude nous avons démontré que les IgA anti-gp41 induisent plus efficacement la phagocytose de cellules infectées par le VIH, que les IgG anti-gp41. Nous avons formulé l'hypothèse que la phagocytose plus importante par les IgA anti-gp41 favoriserait la présentation d'antigènes viraux aux T CD8+ spécifiques du VIH. Pour tester cette hypothèse, nous avons utilisé comme anticorps modèle l'immunoglobuline 2F5 neutralisant le VIH a large spectre de première génération sous forme IgG et IgA. Nous avons mis au point un modèle coculture avec des cellules issues de patients infectés. La caractérisation précise du devenir du monocyte effecteur par des approches de RNA-seq et de cytométrie en flux nous a permit de mettre en avant que les fonctions Fc induites par les IgA favorisent la différenciation des monocytes effecteurs en macrophages. Ceux-ci acquièrent un profil mixte, ce qui permet leur entrainement immunitaire. Par ailleurs, les chémokines sécrétées par les monocytes après ADCP, favorisent le recrutement de neutrophiles, monocytes et T CD8+, associés au contrôle de l'infection chez l'humain. Nos travaux proposent un nouveau mécanisme de protection des anticorps par la phagocytose de cellules entières infectées comme source antigénique et activant le recrutement de cellules immunitaires protectrices. Ces résultats suggèrent également que la présence d'une réponse IgA dirigée contre le VIH-1 permettrait la mise en place d'autres aspects de la réponse immunitaire protectrice de l'infection. Le SARS-CoV-2 a émergé en 2019 et a été rapidement responsable d'une pandémie mondiale, et pour laquelle, aucune approche thérapeutique n'a pu être mise en place efficacement. Le cycle viral se déroule en altérant le métabolisme des lipides en favorisant l'accumulation de gouttelettes lipidiques, mais aussi en parasitant la voie de l'autophagie par inhibition de la fusion des autophagosomes avec les lysosomes. L'activation de la protéine kinase activée par l'AMP, ou AMPK, est possible chimiquement et nous avons voulu déterminer le potentiel antiviral d'un agoniste spécifique, MK-8722. Nous avons montré in vitro que la drogue a un fort potentiel antiviral, qui n'est pas associé à la mort des cellules infectées ni à une altération de l'entrée virale mais d'une restauration du métabolisme lipidique et de la complétion du flux autophagique. Cette inhibition est a été vérifiée après traitement post-infection et se traduit notamment par une restauration de la réponse interféron, essentielle au contrôle de la pathologie à SARS-CoV-2. Nos résultats permettent de proposer une nouvelle classe de molécules antivirales dans les infections virales dépendantes de l'altération du métabolisme lipidique et de l'autophagie, comme le seraient d'autres coronavirus émergents, ou les arbovirus comme le virus de Dengue ou celui de la Fièvre Jaune.
- 7 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Compréhension des mécanismes de la protection des muqueuses contre les infections virales : cas du VIH-1 et du SARS-CoV-2
Les muqueuses sont des épithéliums formant une surface d'interaction avec le milieu extérieur et protègent l'organisme des infections qui découlent de cette interaction. Ces régions anatomiques particulières sont caractérisées par, notamment, des cellules immunitaires résidentes et une réponse IgA majoritaire. Le laboratoire a montré que la présence d'IgA anti-gp41 muqueux est un de corrélats de protection des individus exposés au VIH mais ne se séroconvertissant pas, ainsi que de macaques vaccinés par voie muqueuse. Il a été démontré que l'infusion d'anticorps chez les macaques peut induire une protection contre l'infection SIV/SHIV qui dépend de la réponse T CD8+, aussi impliquée dans le contrôle et la protection contre le VIH chez les humains. Cette observation semble indiquer un rôle de la signalisation par les FcR dans l'induction des réponses T CD8+ spécifiques du VIH mais pour laquelle les mécanismes moléculaires précis manquent de description. L'engagement des FcR sur les cellules myéloïdes induit des fonctions effectrices comme la phagocytose et sont associées à la protection des individus. Au début de cette étude nous avons démontré que les IgA anti-gp41 induisent plus efficacement la phagocytose de cellules infectées par le VIH, que les IgG anti-gp41. Nous avons formulé l'hypothèse que la phagocytose plus importante par les IgA anti-gp41 favoriserait la présentation d'antigènes viraux aux T CD8+ spécifiques du VIH. Pour tester cette hypothèse, nous avons utilisé comme anticorps modèle l'immunoglobuline 2F5 neutralisant le VIH a large spectre de première génération sous forme IgG et IgA. Nous avons mis au point un modèle coculture avec des cellules issues de patients infectés. La caractérisation précise du devenir du monocyte effecteur par des approches de RNA-seq et de cytométrie en flux nous a permit de mettre en avant que les fonctions Fc induites par les IgA favorisent la différenciation des monocytes effecteurs en macrophages. Ceux-ci acquièrent un profil mixte, ce qui permet leur entrainement immunitaire. Par ailleurs, les chémokines sécrétées par les monocytes après ADCP, favorisent le recrutement de neutrophiles, monocytes et T CD8+, associés au contrôle de l'infection chez l'humain. Nos travaux proposent un nouveau mécanisme de protection des anticorps par la phagocytose de cellules entières infectées comme source antigénique et activant le recrutement de cellules immunitaires protectrices. Ces résultats suggèrent également que la présence d'une réponse IgA dirigée contre le VIH-1 permettrait la mise en place d'autres aspects de la réponse immunitaire protectrice de l'infection. Le SARS-CoV-2 a émergé en 2019 et a été rapidement responsable d'une pandémie mondiale, et pour laquelle, aucune approche thérapeutique n'a pu être mise en place efficacement. Le cycle viral se déroule en altérant le métabolisme des lipides en favorisant l'accumulation de gouttelettes lipidiques, mais aussi en parasitant la voie de l'autophagie par inhibition de la fusion des autophagosomes avec les lysosomes. L'activation de la protéine kinase activée par l'AMP, ou AMPK, est possible chimiquement et nous avons voulu déterminer le potentiel antiviral d'un agoniste spécifique, MK-8722. Nous avons montré in vitro que la drogue a un fort potentiel antiviral, qui n'est pas associé à la mort des cellules infectées ni à une altération de l'entrée virale mais d'une restauration du métabolisme lipidique et de la complétion du flux autophagique. Cette inhibition est a été vérifiée après traitement post-infection et se traduit notamment par une restauration de la réponse interféron, essentielle au contrôle de la pathologie à SARS-CoV-2. Nos résultats permettent de proposer une nouvelle classe de molécules antivirales dans les infections virales dépendantes de l'altération du métabolisme lipidique et de l'autophagie, comme le seraient d'autres coronavirus émergents, ou les arbovirus comme le virus de Dengue ou celui de la Fièvre Jaune.
- Open Access
- 24 March 2026
- Published by American Society for Microbiology in Journal of Virology
- Vol. 100 (3) , e0214125
Impact of cellular proteases on the function of antiviral antibodies
Viruses evade antibodies through many mechanisms. While mutation remains the predominant pathway, host proteases can be hijacked upon viral infections and decrease antibody-mediated clearance. Proteolysis can degrade or shed viral antigens to create soluble decoys, induce conformational changes that reduce neutralization, and cleave Fc receptors and complement proteins, hindering Fc-effector antibody functions. This review synthesizes evidence on the interplay between viruses and host proteases to evade antiviral activities of antibodies.
- 24 March 2026
- Published by American Society for Microbiology in Journal of Virology
- Vol. 100 (3) , e0214125
Open AccessImpact of cellular proteases on the function of antiviral antibodies
Viruses evade antibodies through many mechanisms. While mutation remains the predominant pathway, host proteases can be hijacked upon viral infections and decrease antibody-mediated clearance. Proteolysis can degrade or shed viral antigens to create soluble decoys, induce conformational changes that reduce neutralization, and cleave Fc receptors and complement proteins, hindering Fc-effector antibody functions. This review synthesizes evidence on the interplay between viruses and host proteases to evade antiviral activities of antibodies.
- Open Access
TMPRSS2 reduces antibody recognition of SARS-CoV-2 spike
The serine protease TMPRSS2 acts as a cofactor for SARS-CoV-2 entry by cleaving the viral spike (S) to initiate fusion. Whether TMPRSS2 has an impact on humoral immune response against S remains poorly characterized. Here, we show that TMPRSS2 impairs antibody binding to S. In S-expressing and infected cells, TMPRSS2 decreases monoclonal antibody (mAb) and immune serum binding, as well as antibody-dependent cellular cytotoxicity (ADCC) induction. Using a panel of 39 mAbs targeting various S regions, we observe that those binding to the S2 subunit are the most affected by TMPRSS2. TMPRSS2 promotes a partial shedding of S1 and changes S2 conformation. This processing reduces Angiotensin-Converting Enzyme 2 (ACE2) binding while increasing cell-cell fusion. We further observe that the capacity of TMPRSS2 to decrease antibody recognition is conserved across coronaviruses and shared with other TMPRSS proteins. However, TMPRSS2 expression in infected cells does not impact significantly virions’ infectivity or the antibody recognition, as measured by flow virometry. Collectively, our findings suggest that TMPRSS2 processing of S favors a fusion intermediate conformation which is less sensitive to antibody recognition.
Open AccessTMPRSS2 reduces antibody recognition of SARS-CoV-2 spike
The serine protease TMPRSS2 acts as a cofactor for SARS-CoV-2 entry by cleaving the viral spike (S) to initiate fusion. Whether TMPRSS2 has an impact on humoral immune response against S remains poorly characterized. Here, we show that TMPRSS2 impairs antibody binding to S. In S-expressing and infected cells, TMPRSS2 decreases monoclonal antibody (mAb) and immune serum binding, as well as antibody-dependent cellular cytotoxicity (ADCC) induction. Using a panel of 39 mAbs targeting various S regions, we observe that those binding to the S2 subunit are the most affected by TMPRSS2. TMPRSS2 promotes a partial shedding of S1 and changes S2 conformation. This processing reduces Angiotensin-Converting Enzyme 2 (ACE2) binding while increasing cell-cell fusion. We further observe that the capacity of TMPRSS2 to decrease antibody recognition is conserved across coronaviruses and shared with other TMPRSS proteins. However, TMPRSS2 expression in infected cells does not impact significantly virions’ infectivity or the antibody recognition, as measured by flow virometry. Collectively, our findings suggest that TMPRSS2 processing of S favors a fusion intermediate conformation which is less sensitive to antibody recognition.
- Open Access
Direct pharmacological AMPK activation inhibits mucosal SARS-CoV-2 infection by reducing lipid metabolism, restoring autophagy flux and the type I IFN response
AMP-activated protein kinase (AMPK) plays a central role in regulating cell energy balance. When activated, AMPK supresses energy-consuming pathways such as lipid and protein synthesis while increasing nutrient availability through the activation of autophagy. These pathways downstream AMPK activation contribute to SARS-CoV-2 infection, which hijacks autophagy and accumulates lipid droplets in viral factories to support viral replication. Here, we assessed the antiviral activity of the direct pan-AMPK allosteric activator MK-8722 in vitro. MK-8722 efficiently inhibited infection of Alpha and Omicron SARS-CoV-2 variants in Vero76 and human bronchial epithelial Calu-3 cells at micromolar concentration. This inhibition relied on restoring the autophagic flux, which redirected newly synthesized viral proteins for degradation, and on a reduction in lipid metabolism, which affected the viral factories. Furthermore, MK-8722 treatment increased the type I interferon (IFN-I) response. Post-infection treatment with MK-8722 was enough to inhibit efficiently viral replication and restore the IFN-I response. Finally, MK-8722 treatment did not alter the SARS-CoV-2-specific CD8 + T cell response mounted upon Spike vaccination. Overall, by activating AMPK, MK-8722 acts as an effective antiviral against SARS-CoV-2 infection, even when applied post-exposure, paving the way for preclinical tests aimed at inhibiting viral replication and improving patients’ symptoms. Graphical Highlights: MK-8722 exerts post-exposure antiviral activity MK-8722 induces a decrease in cellular lipid content MK-8722 promotes an increase in the autophagic flux of viral components MK-8722 promotes the restoration of the IFN-I activity MK-8722 antiviral activity is compatible with virus-specific T cell responses
Open AccessDirect pharmacological AMPK activation inhibits mucosal SARS-CoV-2 infection by reducing lipid metabolism, restoring autophagy flux and the type I IFN response
AMP-activated protein kinase (AMPK) plays a central role in regulating cell energy balance. When activated, AMPK supresses energy-consuming pathways such as lipid and protein synthesis while increasing nutrient availability through the activation of autophagy. These pathways downstream AMPK activation contribute to SARS-CoV-2 infection, which hijacks autophagy and accumulates lipid droplets in viral factories to support viral replication. Here, we assessed the antiviral activity of the direct pan-AMPK allosteric activator MK-8722 in vitro. MK-8722 efficiently inhibited infection of Alpha and Omicron SARS-CoV-2 variants in Vero76 and human bronchial epithelial Calu-3 cells at micromolar concentration. This inhibition relied on restoring the autophagic flux, which redirected newly synthesized viral proteins for degradation, and on a reduction in lipid metabolism, which affected the viral factories. Furthermore, MK-8722 treatment increased the type I interferon (IFN-I) response. Post-infection treatment with MK-8722 was enough to inhibit efficiently viral replication and restore the IFN-I response. Finally, MK-8722 treatment did not alter the SARS-CoV-2-specific CD8 + T cell response mounted upon Spike vaccination. Overall, by activating AMPK, MK-8722 acts as an effective antiviral against SARS-CoV-2 infection, even when applied post-exposure, paving the way for preclinical tests aimed at inhibiting viral replication and improving patients’ symptoms. Graphical Highlights: MK-8722 exerts post-exposure antiviral activity MK-8722 induces a decrease in cellular lipid content MK-8722 promotes an increase in the autophagic flux of viral components MK-8722 promotes the restoration of the IFN-I activity MK-8722 antiviral activity is compatible with virus-specific T cell responses